Genopathy
Gene-Disorder Association · Article
Gene
TET2
Tet Methylcytosine Dioxygenase 2
Manually curatedApproved treatment annotated
Association Review

In brief

The association between TET2 (Tet Methylcytosine Dioxygenase 2) and Myelodysplastic Syndrome is well established and manually curated, with its 3 contributing sources — 2 of them expert-curated — recording a known molecular basis and likely-pathogenic variants.

Sources 3
Clinical variants 9
Symptoms 1
Compounds 1
Trials 243of 712 via TET2 compounds
Publications 0
01
At a glance

Association overview

A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.

Request access
02
Provenance

Evidence and sources

3 sources

Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.

Request access
03
TET2

The gene

1 source summary

A gene summary alongside the source descriptions it was distilled from.

Request access
04
Myelodysplastic Syndrome

The disorder

11 database identifiers

The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).

Request access
05
Phenotype

Clinical features

1 clinical feature

The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.

Request access
06
ClinVar and variant evidence

Genetic basis

9 clinical variants

ClinVar variants reported for this pair, with disorder-specific significance, review status, molecular consequence and origin.

Request access
07
Mechanism overlap

Shared mechanisms

Biological pathways and phenotype concepts shared by the gene and the disorder, with supporting publications.

Request access
08
Interventions

Therapeutics

1 compound or drug

Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.

Request access
09
Human studies

Clinical trials

712 clinical trials

Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.

Request access
10
Provenance

References & sources

7 references

Every source and publication cited across this dossier, as one numbered reference list.

Request access